Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding
Rattachement africain : no. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Shiga toxin (Stx), an AB5 toxin, binds specifically to the neutral glycosphingolipid Gb3 at the cell surface before being transported into cells. We here demonstrate that addition of conical lysophospholipids (LPLs) with large head groups inhibit Stx binding to cells whereas LPLs with small head groups do not. Lysophosphatidylinositol (LPI 18:0), the most efficient LPL with the largest head group, was selected for in-depth investigations to study how the binding of Stx is regulated. We show that the inhibition of Stx binding by LPI is reversible and possibly regulated by cholesterol since addition of methyl-β-cyclodextrin (mβCD) reversed the ability of LPI to inhibit binding. LPI-induced inhibition of Stx binding is independent of signalling and membrane turnover as it occurs in fixed cells as well as after depletion of cellular ATP. Furthermore, data obtained with fluorescent membrane dyes suggest that LPI treatment has a direct effect on plasma membrane lipid packing with shift towards a liquid disordered phase in the outer leaflet, while lysophosphoethanolamine (LPE), which has a small head group, does not. In conclusion, our data show that cellular treatment with conical LPLs with large head groups changes intrinsic properties of the plasma membrane and modulates Stx binding to Gb3.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding
- Date Crossref
- 26/07/2016
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Oslo University Hospital Department of Molecular Cell Biology pays non établi dans la noticeÉtablissement de santé
-
University of Oslo Department of Biosciences pays non établi dans la noticeUniversité ou école supérieure
-
Østfold Hospital Trust Department of Research and Innovation pays non établi dans la noticeÉtablissement de santé
-
Faculty of Medicine Centre for Cancer Biomedicine pays non établi dans la noticeUniversité ou école supérieure
Department of Molecular Cell Biology — Oslo University Hospital, Department of Biosciences — University of Oslo et Department of Research and Innovation — Østfold Hospital Trust, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.